Late mortality and levamisole adjuvant therapy in colorectal cancer.

Beginning in 1975, 78 patients with resected stage B and C colorectal carcinoma were randomly assigned (2:1) to receive either levamisole 2.5 mg kg-1 day-1 given for 2 days every week for 18 months or placebo therapy in the same schedule. Pretreatment characteristics (age, gender, disease site, CEA...

Descripción completa

Detalles Bibliográficos
Autores principales: Chlebowski, R. T., Lillington, L., Nystrom, J. S., Sayre, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969447/
https://www.ncbi.nlm.nih.gov/pubmed/8198976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969447/
https://www.ncbi.nlm.nih.gov/pubmed/8198976

Ejemplares similares